Table 2.

Cell line killing based on MS evidence of HLA-A*02:ALNEQIARL

Cell lineHLA-A*02/MSNDC80-clC killingNDC80-clE killing
Hematologic malignancies    
 AML14 +/+ +++ + 
 OCI-AML02 +/+ +++ + 
 BV173 +/+ +++ + 
 SUDHL6 +/+ + − 
 MAC2A +/+ +++ + 
 SUDHL4 +/− − − 
 HL60 −/− − − 
Nonhematologic malignancies    
 JMN +/+ +++ + 
 TPC-1 +/+ ++ − 
 MDA-MB231 +/+ ++ − 
 PANC-1 +/+ + − 
 SKMEL-5 +/+ + − 
 HCT116 +/− − − 
 T47D −/− − − 
Cell lineHLA-A*02/MSNDC80-clC killingNDC80-clE killing
Hematologic malignancies    
 AML14 +/+ +++ + 
 OCI-AML02 +/+ +++ + 
 BV173 +/+ +++ + 
 SUDHL6 +/+ + − 
 MAC2A +/+ +++ + 
 SUDHL4 +/− − − 
 HL60 −/− − − 
Nonhematologic malignancies    
 JMN +/+ +++ + 
 TPC-1 +/+ ++ − 
 MDA-MB231 +/+ ++ − 
 PANC-1 +/+ + − 
 SKMEL-5 +/+ + − 
 HCT116 +/− − − 
 T47D −/− − − 
View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal